NASDAQ:OM - US6901452069 - Common Stock
The current stock price of OM is 13.74 USD. In the past month the price decreased by -2.97%. In the past year, price increased by 87.28%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.83 | 228.80B | ||
ISRG | INTUITIVE SURGICAL INC | 58.27 | 168.15B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.69 | 158.04B | ||
SYK | STRYKER CORP | 30.35 | 149.08B | ||
MDT | MEDTRONIC PLC | 16.88 | 119.71B | ||
BDX | BECTON DICKINSON AND CO | 13.19 | 53.93B | ||
IDXX | IDEXX LABORATORIES INC | 53.24 | 51.16B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.82 | 48.01B | ||
RMD | RESMED INC | 28.38 | 39.68B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.36 | 32.69B | ||
DXCM | DEXCOM INC | 43.71 | 29.14B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.11 | 26.06B |
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. The company is headquartered in San Jose, California and currently employs 354 full-time employees. The company went IPO on 2020-09-15. The company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. The company also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
OUTSET MEDICAL INC
3052 Orchard Drive
San Jose CALIFORNIA 95134 US
CEO: Leslie Trigg
Employees: 354
Phone: 16692318200
The current stock price of OM is 13.74 USD. The price decreased by -1.22% in the last trading session.
The exchange symbol of OUTSET MEDICAL INC is OM and it is listed on the Nasdaq exchange.
OM stock is listed on the Nasdaq exchange.
13 analysts have analysed OM and the average price target is 26.27 USD. This implies a price increase of 91.16% is expected in the next year compared to the current price of 13.74. Check the OUTSET MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OUTSET MEDICAL INC (OM) has a market capitalization of 244.16M USD. This makes OM a Micro Cap stock.
OUTSET MEDICAL INC (OM) currently has 354 employees.
OUTSET MEDICAL INC (OM) has a support level at 13.66 and a resistance level at 14.21. Check the full technical report for a detailed analysis of OM support and resistance levels.
The Revenue of OUTSET MEDICAL INC (OM) is expected to grow by 10.07% in the next year. Check the estimates tab for more information on the OM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OM does not pay a dividend.
OUTSET MEDICAL INC (OM) will report earnings on 2025-11-04, after the market close.
OUTSET MEDICAL INC (OM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.48).
The outstanding short interest for OUTSET MEDICAL INC (OM) is 13.29% of its float. Check the ownership tab for more information on the OM short interest.
ChartMill assigns a technical rating of 3 / 10 to OM. When comparing the yearly performance of all stocks, OM is one of the better performing stocks in the market, outperforming 83.83% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to OM. Both the profitability and financial health of OM have multiple concerns.
Over the last trailing twelve months OM reported a non-GAAP Earnings per Share(EPS) of -15.48. The EPS increased by 55.9% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -33.9% | ||
ROE | -63.25% | ||
Debt/Equity | 0.61 |
13 analysts have analysed OM and the average price target is 26.27 USD. This implies a price increase of 91.16% is expected in the next year compared to the current price of 13.74.
For the next year, analysts expect an EPS growth of 83.6% and a revenue growth 10.07% for OM